IC
PVLA

Ikarian Capital’s Palvella Therapeutics PVLA Stock Holding History

Ikarian Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-275
Closed -$80K – 178
2019
Q4 		$80K Buy
+275
New +$76.2K 0.01% 109

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ikarian Capital's PVLA Position: Q2 2026 in Review

Ikarian Capital sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 64,626 shares — an estimated $8.06M sold.

Ikarian Capital first reported a position in PVLA in Q3 2025 and held it in 2 quarters. The position peaked at $8.06M in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Ikarian Capital reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ikarian Capital sold 64,626 Palvella Therapeutics shares in Q2 2026, an estimated $8.06M.
  • Ikarian Capital first reported a position in Palvella Therapeutics in Q3 2025 and held it in 2 quarters.
  • Ikarian Capital's Palvella Therapeutics position peaked at $8.06M in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.